Aardvark grants director 44,964 options at $6.54

Q: What insider transaction did AARD report for Jeffrey Chi on this Form 4?

Aardvark Therapeutics, Inc. reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026, as an equity award. These are derivative securities giving him the right to purchase AARD common stock in the future.

Q: How many AARD stock options did Jeffrey Chi hold after this reported grant?

Following the August 14, 2026 grant, Jeffrey Chi held 44,964 stock options directly. This amount reflects the total number of options reported as beneficially owned after the transaction on this Form 4.

Q: When do Jeffrey Chi’s newly granted AARD stock options vest?

The options vest in full on the earlier of August 14, 2027 or immediately prior to Aardvark Therapeutics, Inc.’s next Annual Meeting of Stockholders following the grant date, provided Jeffrey Chi remains in continuous service through the applicable vesting date.

Aardvark Therapeutics, Inc. (AARD) reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aardvark Therapeutics, Inc. (AARD) reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026. The options have an exercise price of $6.54 per share and expire on August 14, 2036. According to the terms, the option vests in full on the earlier of August 14, 2027 or immediately prior to the company’s next Annual Meeting of Stockholders following the grant date, subject to his continuous service through the applicable vesting date.

Insider Trade Summary

Grant/Award: 44,964 shares

Grant/Award 1 txn

Insider Chi Jeffrey

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) ^F1	44,964	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 44,964 contracts (Direct)

Footnotes (1)

F1. The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.

Key Figures

Stock options granted: 44,964 options Exercise price: $6.54 per share Expiration date: August 14, 2036 +2 more

5 metrics

Stock options granted 44,964 options Grant to director Jeffrey Chi on August 14, 2026

Exercise price $6.54 per share Exercise price for the 44,964 stock options

Expiration date August 14, 2036 Expiration of stock options granted to Jeffrey Chi

Shares underlying options 44,964 shares of Common Stock Underlying Aardvark Therapeutics, Inc. common shares for the options

Latest vesting date August 14, 2027 Latest possible full vesting date, subject to earlier vesting before next Annual Meeting

Key Terms

Stock Option (right to buy), vesting, Annual Meeting of Stockholders

3 terms

Stock Option (right to buy) financial

"Reported security title was "Stock Option (right to buy)""

vesting financial

"The option shall vest in full on the earlier of (i) August 14, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders regulatory

"immediately prior to the Registrant's next Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AARD report for Jeffrey Chi on this Form 4?

Aardvark Therapeutics, Inc. reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026, as an equity award. These are derivative securities giving him the right to purchase AARD common stock in the future.

What is the exercise price of the new stock options granted by AARD to Jeffrey Chi?

The stock options granted to Jeffrey Chi have an exercise price of $6.54 per share. This is the price at which he may purchase Aardvark Therapeutics, Inc. common stock upon exercising the options, once they are vested and exercisable.

How many AARD stock options did Jeffrey Chi hold after this reported grant?

Following the August 14, 2026 grant, Jeffrey Chi held 44,964 stock options directly. This amount reflects the total number of options reported as beneficially owned after the transaction on this Form 4.

When do Jeffrey Chi’s newly granted AARD stock options vest?

The options vest in full on the earlier of August 14, 2027 or immediately prior to Aardvark Therapeutics, Inc.’s next Annual Meeting of Stockholders following the grant date, provided Jeffrey Chi remains in continuous service through the applicable vesting date.

When do the AARD stock options granted to Jeffrey Chi expire?

The stock options granted to Jeffrey Chi on August 14, 2026 expire on August 14, 2036. After this expiration date, any unexercised options will no longer be exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/21/2026 - 07:49 PM Accepted by SEC EDGAR 08/21/2026 - 07:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chi Jeffrey

(Last)

(First)

(Middle)

C/O AARDVARK THERAPEUTICS, INC.

4370 LA JOLLA VILLAGE DRIVE, SUITE 1050

(Street)

SAN DIEGO

CALIFORNIA

92122

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aardvark Therapeutics, Inc. [ AARD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.54	08/14/2026		A		44,964		⁽¹⁾	08/14/2036	Common Stock	44,964	$0.00	44,964	D

Explanation of Responses:

1. The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.

	/s/ Nelson Sun, as Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR